Lv21
150 积分 2024-02-06 加入
Efgartigimod as a novel FcRn inhibitor for autoimmune disease
49分钟前
待确认
Opportunities and limitations of B cell depletion approaches in SLE
1个月前
已完结
Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia
1个月前
已完结
B cell dysregulation and depletion therapy in primary membranous nephropathy: Prospects and potential challenges
1个月前
已完结
Macrophages: versatile players in renal inflammation and fibrosis
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
3个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
3个月前
已完结
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry
3个月前
已完结
Pembrolizumab plus enfortumab vedotin in urothelial cancer
4个月前
已完结
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
4个月前
已完结
皖公网安备34019202002308
